We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Impact of Asthma Treatments on Daily Activities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00350376
Recruitment Status : Unknown
Verified July 2006 by Ovation Research Group.
Recruitment status was:  Recruiting
First Posted : July 10, 2006
Last Update Posted : July 10, 2006
Genentech, Inc.
Information provided by:
Ovation Research Group

Brief Summary:
The primary objective of this web-based, cross-sectional study is to assess and compare the ability to sleep, work or go to school, and to participate in leisure activities among subjects who are receiving Xolair treatment and subjects who were eligible to receive Xolair, but instead have been using Advair for at least 1 year.

Condition or disease
Asthma Allergies

Study Type : Observational
Estimated Enrollment : 1500 participants
Observational Model: Defined Population
Time Perspective: Cross-Sectional
Time Perspective: Retrospective
Official Title: Study on Asthma Treatments on Daily Activities as Reported by Patients (STAR)
Study Start Date : June 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Asthma
U.S. FDA Resources

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Have asthma and allergies
  • Currently taking Xolair® or Advair®
  • Started Xolair® treatment within the last 4 to 12 months OR have been taking Advair® for at least 12 months
  • Between 18 and 55 years of age
  • A non-smoker for at least 6 months
  • Have internet access

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00350376

Contact: Nita Ngo, MPH 888.631.9167 asthmastudy@ovation.org

United States, California
Ovation Research Group Recruiting
San Francisco, California, United States, 94105
Principal Investigator: Susan D Mathias, MPH         
Sponsors and Collaborators
Ovation Research Group
Genentech, Inc.
Principal Investigator: Susan D Mathias, MPH Ovation Research Group

ClinicalTrials.gov Identifier: NCT00350376     History of Changes
Other Study ID Numbers: 1467
First Posted: July 10, 2006    Key Record Dates
Last Update Posted: July 10, 2006
Last Verified: July 2006

Keywords provided by Ovation Research Group:

Additional relevant MeSH terms:
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Immune System Diseases